Articles & Video
REPORT: COVID-19 Response in Cell & Gene Therapy Manufacturing 2021
This exclusive report uncovers the major changes in the cell and gene therapy sector during the COVID-19 pandemic.
Ebook: The Future of the Cell and Gene Therapy Industry
What can we expect next from the cell and gene therapy sector? This ebook explores the potential paths ahead, from optimized CAR-T to automated bioprocessing.
Advancing Gene Therapies: Evaluating Immunogenicity and its Impact on Therapeutic Potential
What are the considerations for selecting the best immunogenicity assay?
Survey: Cell & Gene Therapy COVID-19 Response
What changes are happening in the cell and gene therapy sector as a result of the pandemic? Tell us your experience.
Viral vectors have biggest limitations in vector manufacturing, according to industry survey
Exploring results of our industry survey, we identify the biggest pain points in vector manufacturing experienced by cell and gene therapy professionals.
Vector manufacturing for cell and gene therapies: how should current platforms be changed?
What do we need from vector manufacturing platforms to deliver commercial scale therapies? We look at responses from industry insiders.
Novel analytical strategies and tools for cell and gene therapies - WHITEPAPER
What analytical techniques can be applied to production of cell therapies, gene therapies and gene-edited cell-therapies? This whitepaper looks at the latest examples.
Automating cell and gene therapy manufacturing: challenges and approaches
With the pressure on to scale up manufacturing of cell and gene therapies, what steps should organizations take to optimize their processes with automation? We asked three industry experts for their advice.
Why gene therapy lotteries are good for patients, providers, and manufacturers
Jeremy Schafer, PharmD, MBA argues how drug lotteries like Novartis' new program could mean a fairer and more beneficial system for all.
Does Zolgensma’s success predict similar rapid uptake of gene therapy for Hemophilia?
Doe the success of Zolgensma mean payers will be as welcoming to the cost and volume of hemophilia gene therapy or will payers wait for competition?
The success of gene therapy depends on…diagnostic testing
It is little recognized that gene therapy success depends on the appropriate application of one or more specialized diagnostic tests.
Key regulatory considerations around cell and gene therapies - WHITEPAPER
This whitepaper explores regulatory concerns associated with the development of cell and gene therapy products, as well as fast track market authorization.
The commercialization of cell and gene therapies - WHITEPAPER
The commercialization of cell and gene therapies is already underway, but has an exciting future - this whitepaper explores both.
The rise of patient-specific autologous cell therapies with Dr Mark Lowdell, UCL, RFH
Dr Mark Lowdell, Director of Cellular Therapy & Biobanking at Royal Free London NHS Foundation Trust, explores the rapid commercialization of CAR-T therapies.